IRCT20220111053692N4招募中未知
Bioequivalence study of Rivaroxaban 20 mg tablet (Tehran Darou) versus Xalerto® 20 mg (Bayer) Tablet after single oral dosing in healthy volunteers
tehran darou Pharmaceutical Company0 个研究点目标入组 24 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 55 years（—）
- 性别
- Male
入选标准
- •18 to 55 years old
- •Weight in range of 10 % proper body weight
- •All volunteers should be in a good health condition on the basis of medical history, physical examination, routine blood test.
- •and possessing negative test for hepatitis B surface antigen (HBs-Ag), antihepatitis-C antibody (anti-HCV), and anti-HIV.
排除标准
- •Volunteers with hypersensitivity to Rivaroxaban were excluded.
- •those with known history of drug abuse. alcohol consumer or cigarette smokers.
- •Taking medications that have drug interactions with Metformin until one month before studying.
- •disinclination to take the test
- •Blood donation or blood loss of more than 200 ml in the past month
研究者
相似试验
尚未招募
Unknown
Bioequivalence study of Rivaroxaban 20mg tabletIRCT20200623047902N28Darou Darman Arang company24
尚未招募
不适用
In-vivo Bioequivalence Test of Rivaroxaban® tablet with brand drugs (Xarelto® Bayer, Germany).IRCT20200105046010N27Jaber Ibn Hayyan Pharmaceutical Company24
已完成
1 期
Bioequivalence Study of Rivaroxaban in Japanese Healthy Adult Male SubjectsEmbolism, Atrial Fibrillation and Venous ThrombosisNCT02537405Bayer40
尚未招募
不适用
A bioequivalence study of Rivaroxaban 20 mg tab compared to Xarelto 20 mg tab manufactured by Bayer in 24 healthy volunteers under fasting conditioIRCT20220209053979N1Pars Darou24
已完成
1 期
Bioequivalence Study of Rivaroxaban 20 mg Film-coated TabletsHealthyNCT06558045Dexa Medica Group26